Edgar Charles III, MD, Infectious Disease, Princeton, NJ, VA NY Harbor Healthcare System, Manhattan Campus

EdgarDavdisonCharlesIIIMD

Infectious Disease Princeton, NJ

Physician

Dr. Charles is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Charles' full profile

Already have an account?

Summary

  • I am an infectious disease-trained physician-scientist with deep translational and clinical experience in hepatology, immunology, infectious diseases, autoimmunity and fibrosis. Broad clinical research experience in early and late stage drug development, including immunopathogenesis basic/translational research, target identification, biomarker identification, Phase 0-4 trials, and FDA registration.

Education & Training

  • Rockefeller UniversityOTHER_TRAINING
  • NYU School of Medicine
    NYU School of MedicineFELLOWSHIP
  • NYU School of Medicine
    NYU School of MedicineRESIDENCY
  • University of Alabama School of Medicine
    University of Alabama School of MedicineMEDICAL_SCHOOL
  • University of ChicagoOTHER_TRAINING

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2001 - 2022
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • A Phase 2 Study of BMS-986036 (Pegylated FGF21) for 12 Weeks in Obese Adults with Type 2 Diabetes Mellitus (T2DM) and a High Prevalence of Fatty Liver
    Edgar D. Charles, Brent A. Neuschwander-Tetri, Yi Luo, Chunyu Kate Wu, Rose Christian, American Association for the Study of Liver Disease, Boston, 11/13/2016
  • A Phase 1 Study of BMS-986171 (Pegylated FGF21) in Healthy Obese Subjects
    Chunyu Kate Wu1, Edgar D. Charles, Anh Bui, Rose Christian, Malaz AbuTarif, American Association for the Study of Liver Disease, Boston, 11/12/2016
  • A Phase 1 Study of BMS-986036 (Pegylated FGF21) in Healthy Obese Subjects
    Edgar D. Charles, Linda Morrow, Marcus Hompesch, Yi Luo, Chunyu Kate Wu, Rose Christian, American Association for the Study of Liver Disease, Boston, 10/12/2016
  • Join now to see all

Grant Support

  • The Pathogenesis Of Autoimmunity In Hepatitis C Virus InfectionNational Institute Of Allergy And Infectious Diseases2008–2012

Hospital Affiliations